nodes	percent_of_prediction	percent_of_DWPC	metapath
Eprosartan—ABCC2—Vincristine—peripheral nervous system neoplasm	0.138	0.221	CbGbCtD
Eprosartan—ABCC2—Cisplatin—peripheral nervous system neoplasm	0.128	0.206	CbGbCtD
Eprosartan—ABCC2—Etoposide—peripheral nervous system neoplasm	0.126	0.203	CbGbCtD
Eprosartan—CYP2C9—Tretinoin—peripheral nervous system neoplasm	0.101	0.162	CbGbCtD
Eprosartan—ABCC2—Doxorubicin—peripheral nervous system neoplasm	0.086	0.138	CbGbCtD
Eprosartan—CYP2C9—Cisplatin—peripheral nervous system neoplasm	0.0431	0.0693	CbGbCtD
Eprosartan—AGTR1—ACE Inhibitor Pathway—KNG1—peripheral nervous system neoplasm	0.000648	0.0911	CbGpPWpGaD
Eprosartan—ABCC2—Codeine and Morphine Metabolism—ABCB1—peripheral nervous system neoplasm	0.000634	0.0892	CbGpPWpGaD
Eprosartan—AGTR1—Arf6 trafficking events—NME1—peripheral nervous system neoplasm	0.000613	0.0862	CbGpPWpGaD
Eprosartan—ABCC2—Irinotecan Pathway—BCHE—peripheral nervous system neoplasm	0.000538	0.0757	CbGpPWpGaD
Eprosartan—ABCC2—Drug Induction of Bile Acid Pathway—ABCB1—peripheral nervous system neoplasm	0.000347	0.0488	CbGpPWpGaD
Eprosartan—AGTR1—Arf6 signaling events—HGF—peripheral nervous system neoplasm	0.000303	0.0426	CbGpPWpGaD
Eprosartan—Tachycardia—Cisplatin—peripheral nervous system neoplasm	0.000301	0.000812	CcSEcCtD
Eprosartan—Dermatitis—Isotretinoin—peripheral nervous system neoplasm	0.000301	0.000812	CcSEcCtD
Eprosartan—Dermatitis—Tretinoin—peripheral nervous system neoplasm	0.000301	0.000812	CcSEcCtD
Eprosartan—Fatigue—Vincristine—peripheral nervous system neoplasm	0.000301	0.000811	CcSEcCtD
Eprosartan—Vomiting—Melphalan—peripheral nervous system neoplasm	0.0003	0.000809	CcSEcCtD
Eprosartan—Hyponatraemia—Doxorubicin—peripheral nervous system neoplasm	0.0003	0.000808	CcSEcCtD
Eprosartan—Headache—Isotretinoin—peripheral nervous system neoplasm	0.0003	0.000807	CcSEcCtD
Eprosartan—Headache—Tretinoin—peripheral nervous system neoplasm	0.0003	0.000807	CcSEcCtD
Eprosartan—Feeling abnormal—Alitretinoin—peripheral nervous system neoplasm	0.000299	0.000805	CcSEcCtD
Eprosartan—Constipation—Vincristine—peripheral nervous system neoplasm	0.000299	0.000805	CcSEcCtD
Eprosartan—Pain—Vincristine—peripheral nervous system neoplasm	0.000299	0.000805	CcSEcCtD
Eprosartan—Osteoarthritis—Doxorubicin—peripheral nervous system neoplasm	0.000299	0.000804	CcSEcCtD
Eprosartan—Hyperhidrosis—Cisplatin—peripheral nervous system neoplasm	0.000299	0.000804	CcSEcCtD
Eprosartan—Rash—Melphalan—peripheral nervous system neoplasm	0.000298	0.000802	CcSEcCtD
Eprosartan—Dermatitis—Melphalan—peripheral nervous system neoplasm	0.000297	0.000801	CcSEcCtD
Eprosartan—Gastrointestinal pain—Alitretinoin—peripheral nervous system neoplasm	0.000296	0.000799	CcSEcCtD
Eprosartan—Chest pain—Etoposide—peripheral nervous system neoplasm	0.000295	0.000795	CcSEcCtD
Eprosartan—Orthostatic hypotension—Epirubicin—peripheral nervous system neoplasm	0.000295	0.000794	CcSEcCtD
Eprosartan—Anorexia—Cisplatin—peripheral nervous system neoplasm	0.000294	0.000793	CcSEcCtD
Eprosartan—Migraine—Doxorubicin—peripheral nervous system neoplasm	0.000294	0.000792	CcSEcCtD
Eprosartan—Hypokalaemia—Epirubicin—peripheral nervous system neoplasm	0.000294	0.000791	CcSEcCtD
Eprosartan—Discomfort—Etoposide—peripheral nervous system neoplasm	0.000292	0.000786	CcSEcCtD
Eprosartan—Aspartate aminotransferase increased—Epirubicin—peripheral nervous system neoplasm	0.000291	0.000783	CcSEcCtD
Eprosartan—Hypotension—Cisplatin—peripheral nervous system neoplasm	0.000289	0.000778	CcSEcCtD
Eprosartan—Face oedema—Doxorubicin—peripheral nervous system neoplasm	0.000288	0.000777	CcSEcCtD
Eprosartan—Hypersensitivity—Dactinomycin—peripheral nervous system neoplasm	0.000288	0.000776	CcSEcCtD
Eprosartan—Urticaria—Alitretinoin—peripheral nervous system neoplasm	0.000288	0.000776	CcSEcCtD
Eprosartan—Abdominal pain—Alitretinoin—peripheral nervous system neoplasm	0.000287	0.000772	CcSEcCtD
Eprosartan—Body temperature increased—Alitretinoin—peripheral nervous system neoplasm	0.000287	0.000772	CcSEcCtD
Eprosartan—Nausea—Topotecan—peripheral nervous system neoplasm	0.000286	0.000772	CcSEcCtD
Eprosartan—Gastrointestinal pain—Vincristine—peripheral nervous system neoplasm	0.000286	0.00077	CcSEcCtD
Eprosartan—Gastritis—Epirubicin—peripheral nervous system neoplasm	0.000286	0.000769	CcSEcCtD
Eprosartan—Muscular weakness—Epirubicin—peripheral nervous system neoplasm	0.000285	0.000767	CcSEcCtD
Eprosartan—Alanine aminotransferase increased—Epirubicin—peripheral nervous system neoplasm	0.000285	0.000767	CcSEcCtD
Eprosartan—Nausea—Tretinoin—peripheral nervous system neoplasm	0.000284	0.000765	CcSEcCtD
Eprosartan—Nausea—Isotretinoin—peripheral nervous system neoplasm	0.000284	0.000765	CcSEcCtD
Eprosartan—Musculoskeletal discomfort—Cisplatin—peripheral nervous system neoplasm	0.000281	0.000758	CcSEcCtD
Eprosartan—Ataxia—Doxorubicin—peripheral nervous system neoplasm	0.000281	0.000756	CcSEcCtD
Eprosartan—Asthenia—Dactinomycin—peripheral nervous system neoplasm	0.000281	0.000756	CcSEcCtD
Eprosartan—Nausea—Melphalan—peripheral nervous system neoplasm	0.00028	0.000756	CcSEcCtD
Eprosartan—Blood creatinine increased—Doxorubicin—peripheral nervous system neoplasm	0.00028	0.000754	CcSEcCtD
Eprosartan—Asthma—Epirubicin—peripheral nervous system neoplasm	0.000279	0.000751	CcSEcCtD
Eprosartan—Paraesthesia—Cisplatin—peripheral nervous system neoplasm	0.000277	0.000747	CcSEcCtD
Eprosartan—Thrombocytopenia—Etoposide—peripheral nervous system neoplasm	0.000277	0.000746	CcSEcCtD
Eprosartan—Tachycardia—Etoposide—peripheral nervous system neoplasm	0.000276	0.000744	CcSEcCtD
Eprosartan—Abdominal pain—Vincristine—peripheral nervous system neoplasm	0.000276	0.000744	CcSEcCtD
Eprosartan—Body temperature increased—Vincristine—peripheral nervous system neoplasm	0.000276	0.000744	CcSEcCtD
Eprosartan—Dyspnoea—Cisplatin—peripheral nervous system neoplasm	0.000275	0.000742	CcSEcCtD
Eprosartan—Hyperhidrosis—Etoposide—peripheral nervous system neoplasm	0.000274	0.000737	CcSEcCtD
Eprosartan—Orthostatic hypotension—Doxorubicin—peripheral nervous system neoplasm	0.000273	0.000735	CcSEcCtD
Eprosartan—Hypokalaemia—Doxorubicin—peripheral nervous system neoplasm	0.000272	0.000732	CcSEcCtD
Eprosartan—Angina pectoris—Epirubicin—peripheral nervous system neoplasm	0.000272	0.000732	CcSEcCtD
Eprosartan—Anorexia—Etoposide—peripheral nervous system neoplasm	0.00027	0.000727	CcSEcCtD
Eprosartan—Aspartate aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	0.000269	0.000724	CcSEcCtD
Eprosartan—Decreased appetite—Cisplatin—peripheral nervous system neoplasm	0.000269	0.000723	CcSEcCtD
Eprosartan—Bronchitis—Epirubicin—peripheral nervous system neoplasm	0.000268	0.000723	CcSEcCtD
Eprosartan—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	0.000268	0.000721	CcSEcCtD
Eprosartan—Hypersensitivity—Alitretinoin—peripheral nervous system neoplasm	0.000267	0.00072	CcSEcCtD
Eprosartan—Hypotension—Etoposide—peripheral nervous system neoplasm	0.000264	0.000712	CcSEcCtD
Eprosartan—Gastritis—Doxorubicin—peripheral nervous system neoplasm	0.000264	0.000712	CcSEcCtD
Eprosartan—Pain—Cisplatin—peripheral nervous system neoplasm	0.000264	0.000712	CcSEcCtD
Eprosartan—Alanine aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	0.000263	0.00071	CcSEcCtD
Eprosartan—Muscular weakness—Doxorubicin—peripheral nervous system neoplasm	0.000263	0.00071	CcSEcCtD
Eprosartan—Asthenia—Alitretinoin—peripheral nervous system neoplasm	0.00026	0.000701	CcSEcCtD
Eprosartan—Upper respiratory tract infection—Epirubicin—peripheral nervous system neoplasm	0.000259	0.000698	CcSEcCtD
Eprosartan—Asthma—Doxorubicin—peripheral nervous system neoplasm	0.000258	0.000695	CcSEcCtD
Eprosartan—Pollakiuria—Epirubicin—peripheral nervous system neoplasm	0.000258	0.000694	CcSEcCtD
Eprosartan—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	0.000257	0.000693	CcSEcCtD
Eprosartan—Pruritus—Alitretinoin—peripheral nervous system neoplasm	0.000256	0.000691	CcSEcCtD
Eprosartan—Feeling abnormal—Cisplatin—peripheral nervous system neoplasm	0.000255	0.000686	CcSEcCtD
Eprosartan—Paraesthesia—Etoposide—peripheral nervous system neoplasm	0.000254	0.000685	CcSEcCtD
Eprosartan—Dyspnoea—Etoposide—peripheral nervous system neoplasm	0.000252	0.00068	CcSEcCtD
Eprosartan—Hyperglycaemia—Epirubicin—peripheral nervous system neoplasm	0.000252	0.000678	CcSEcCtD
Eprosartan—Somnolence—Etoposide—peripheral nervous system neoplasm	0.000252	0.000678	CcSEcCtD
Eprosartan—Angina pectoris—Doxorubicin—peripheral nervous system neoplasm	0.000251	0.000677	CcSEcCtD
Eprosartan—Asthenia—Vincristine—peripheral nervous system neoplasm	0.000251	0.000675	CcSEcCtD
Eprosartan—Vomiting—Dactinomycin—peripheral nervous system neoplasm	0.000249	0.00067	CcSEcCtD
Eprosartan—Bronchitis—Doxorubicin—peripheral nervous system neoplasm	0.000248	0.000669	CcSEcCtD
Eprosartan—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	0.000248	0.000668	CcSEcCtD
Eprosartan—Rash—Dactinomycin—peripheral nervous system neoplasm	0.000247	0.000664	CcSEcCtD
Eprosartan—Decreased appetite—Etoposide—peripheral nervous system neoplasm	0.000246	0.000663	CcSEcCtD
Eprosartan—Renal failure—Epirubicin—peripheral nervous system neoplasm	0.000244	0.000659	CcSEcCtD
Eprosartan—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	0.000244	0.000658	CcSEcCtD
Eprosartan—Fatigue—Etoposide—peripheral nervous system neoplasm	0.000244	0.000657	CcSEcCtD
Eprosartan—Neuropathy peripheral—Epirubicin—peripheral nervous system neoplasm	0.000244	0.000657	CcSEcCtD
Eprosartan—Pain—Etoposide—peripheral nervous system neoplasm	0.000242	0.000652	CcSEcCtD
Eprosartan—Constipation—Etoposide—peripheral nervous system neoplasm	0.000242	0.000652	CcSEcCtD
Eprosartan—Urinary tract infection—Epirubicin—peripheral nervous system neoplasm	0.000242	0.000651	CcSEcCtD
Eprosartan—Conjunctivitis—Epirubicin—peripheral nervous system neoplasm	0.000242	0.000651	CcSEcCtD
Eprosartan—Upper respiratory tract infection—Doxorubicin—peripheral nervous system neoplasm	0.00024	0.000646	CcSEcCtD
Eprosartan—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.00024	0.000646	CcSEcCtD
Eprosartan—Diarrhoea—Vincristine—peripheral nervous system neoplasm	0.000239	0.000644	CcSEcCtD
Eprosartan—AGTR1—Arf6 signaling events—MET—peripheral nervous system neoplasm	0.000239	0.0336	CbGpPWpGaD
Eprosartan—Pollakiuria—Doxorubicin—peripheral nervous system neoplasm	0.000238	0.000642	CcSEcCtD
Eprosartan—Haematuria—Epirubicin—peripheral nervous system neoplasm	0.000237	0.000639	CcSEcCtD
Eprosartan—Epistaxis—Epirubicin—peripheral nervous system neoplasm	0.000235	0.000632	CcSEcCtD
Eprosartan—Sinusitis—Epirubicin—peripheral nervous system neoplasm	0.000233	0.000629	CcSEcCtD
Eprosartan—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	0.000233	0.000628	CcSEcCtD
Eprosartan—Hyperglycaemia—Doxorubicin—peripheral nervous system neoplasm	0.000233	0.000627	CcSEcCtD
Eprosartan—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.000232	0.000626	CcSEcCtD
Eprosartan—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	0.000231	0.000623	CcSEcCtD
Eprosartan—Dizziness—Vincristine—peripheral nervous system neoplasm	0.000231	0.000622	CcSEcCtD
Eprosartan—Vomiting—Alitretinoin—peripheral nervous system neoplasm	0.00023	0.000621	CcSEcCtD
Eprosartan—Rash—Alitretinoin—peripheral nervous system neoplasm	0.000229	0.000616	CcSEcCtD
Eprosartan—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	0.000228	0.000615	CcSEcCtD
Eprosartan—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	0.000228	0.000613	CcSEcCtD
Eprosartan—Bradycardia—Epirubicin—peripheral nervous system neoplasm	0.000227	0.000612	CcSEcCtD
Eprosartan—Headache—Alitretinoin—peripheral nervous system neoplasm	0.000227	0.000612	CcSEcCtD
Eprosartan—Renal failure—Doxorubicin—peripheral nervous system neoplasm	0.000226	0.000609	CcSEcCtD
Eprosartan—Neuropathy peripheral—Doxorubicin—peripheral nervous system neoplasm	0.000226	0.000608	CcSEcCtD
Eprosartan—Urticaria—Etoposide—peripheral nervous system neoplasm	0.000225	0.000606	CcSEcCtD
Eprosartan—Rhinitis—Epirubicin—peripheral nervous system neoplasm	0.000224	0.000603	CcSEcCtD
Eprosartan—Body temperature increased—Etoposide—peripheral nervous system neoplasm	0.000224	0.000603	CcSEcCtD
Eprosartan—Abdominal pain—Etoposide—peripheral nervous system neoplasm	0.000224	0.000603	CcSEcCtD
Eprosartan—Conjunctivitis—Doxorubicin—peripheral nervous system neoplasm	0.000224	0.000603	CcSEcCtD
Eprosartan—Urinary tract infection—Doxorubicin—peripheral nervous system neoplasm	0.000224	0.000603	CcSEcCtD
Eprosartan—Vomiting—Vincristine—peripheral nervous system neoplasm	0.000222	0.000598	CcSEcCtD
Eprosartan—Asthenia—Cisplatin—peripheral nervous system neoplasm	0.000222	0.000597	CcSEcCtD
Eprosartan—Pharyngitis—Epirubicin—peripheral nervous system neoplasm	0.000222	0.000597	CcSEcCtD
Eprosartan—Rash—Vincristine—peripheral nervous system neoplasm	0.00022	0.000593	CcSEcCtD
Eprosartan—Dermatitis—Vincristine—peripheral nervous system neoplasm	0.00022	0.000593	CcSEcCtD
Eprosartan—Oedema peripheral—Epirubicin—peripheral nervous system neoplasm	0.00022	0.000593	CcSEcCtD
Eprosartan—Haematuria—Doxorubicin—peripheral nervous system neoplasm	0.000219	0.000591	CcSEcCtD
Eprosartan—Headache—Vincristine—peripheral nervous system neoplasm	0.000219	0.00059	CcSEcCtD
Eprosartan—Epistaxis—Doxorubicin—peripheral nervous system neoplasm	0.000217	0.000585	CcSEcCtD
Eprosartan—Sinusitis—Doxorubicin—peripheral nervous system neoplasm	0.000216	0.000582	CcSEcCtD
Eprosartan—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.000215	0.00058	CcSEcCtD
Eprosartan—Visual impairment—Epirubicin—peripheral nervous system neoplasm	0.000215	0.00058	CcSEcCtD
Eprosartan—AGTR1—G alpha (q) signalling events—NTS—peripheral nervous system neoplasm	0.000212	0.0298	CbGpPWpGaD
Eprosartan—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	0.000211	0.000569	CcSEcCtD
Eprosartan—Bradycardia—Doxorubicin—peripheral nervous system neoplasm	0.00021	0.000567	CcSEcCtD
Eprosartan—ABCC2—Constitutive Androstane Receptor Pathway—ABCB1—peripheral nervous system neoplasm	0.000209	0.0294	CbGpPWpGaD
Eprosartan—AGTR1—Peptide ligand-binding receptors—NTS—peripheral nervous system neoplasm	0.000209	0.0294	CbGpPWpGaD
Eprosartan—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	0.000208	0.000562	CcSEcCtD
Eprosartan—Tinnitus—Epirubicin—peripheral nervous system neoplasm	0.000208	0.000561	CcSEcCtD
Eprosartan—Nausea—Vincristine—peripheral nervous system neoplasm	0.000207	0.000559	CcSEcCtD
Eprosartan—Rhinitis—Doxorubicin—peripheral nervous system neoplasm	0.000207	0.000558	CcSEcCtD
Eprosartan—Pharyngitis—Doxorubicin—peripheral nervous system neoplasm	0.000205	0.000552	CcSEcCtD
Eprosartan—Oedema peripheral—Doxorubicin—peripheral nervous system neoplasm	0.000204	0.000548	CcSEcCtD
Eprosartan—Asthenia—Etoposide—peripheral nervous system neoplasm	0.000203	0.000547	CcSEcCtD
Eprosartan—Chills—Epirubicin—peripheral nervous system neoplasm	0.0002	0.00054	CcSEcCtD
Eprosartan—Pruritus—Etoposide—peripheral nervous system neoplasm	0.0002	0.000539	CcSEcCtD
Eprosartan—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—peripheral nervous system neoplasm	0.000199	0.028	CbGpPWpGaD
Eprosartan—Visual impairment—Doxorubicin—peripheral nervous system neoplasm	0.000199	0.000536	CcSEcCtD
Eprosartan—Vomiting—Cisplatin—peripheral nervous system neoplasm	0.000196	0.000529	CcSEcCtD
Eprosartan—Rash—Cisplatin—peripheral nervous system neoplasm	0.000195	0.000525	CcSEcCtD
Eprosartan—Dermatitis—Cisplatin—peripheral nervous system neoplasm	0.000195	0.000524	CcSEcCtD
Eprosartan—Diarrhoea—Etoposide—peripheral nervous system neoplasm	0.000194	0.000522	CcSEcCtD
Eprosartan—Tinnitus—Doxorubicin—peripheral nervous system neoplasm	0.000193	0.000519	CcSEcCtD
Eprosartan—Flatulence—Epirubicin—peripheral nervous system neoplasm	0.000192	0.000516	CcSEcCtD
Eprosartan—Tension—Epirubicin—peripheral nervous system neoplasm	0.000191	0.000514	CcSEcCtD
Eprosartan—ABCC2—ABC-family proteins mediated transport—ABCB1—peripheral nervous system neoplasm	0.00019	0.0268	CbGpPWpGaD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—NTS—peripheral nervous system neoplasm	0.000189	0.0266	CbGpPWpGaD
Eprosartan—Nervousness—Epirubicin—peripheral nervous system neoplasm	0.000189	0.000509	CcSEcCtD
Eprosartan—Back pain—Epirubicin—peripheral nervous system neoplasm	0.000188	0.000506	CcSEcCtD
Eprosartan—Dizziness—Etoposide—peripheral nervous system neoplasm	0.000187	0.000504	CcSEcCtD
Eprosartan—Muscle spasms—Epirubicin—peripheral nervous system neoplasm	0.000187	0.000503	CcSEcCtD
Eprosartan—Chills—Doxorubicin—peripheral nervous system neoplasm	0.000185	0.000499	CcSEcCtD
Eprosartan—Nausea—Cisplatin—peripheral nervous system neoplasm	0.000183	0.000494	CcSEcCtD
Eprosartan—Ill-defined disorder—Epirubicin—peripheral nervous system neoplasm	0.00018	0.000486	CcSEcCtD
Eprosartan—Vomiting—Etoposide—peripheral nervous system neoplasm	0.00018	0.000485	CcSEcCtD
Eprosartan—Rash—Etoposide—peripheral nervous system neoplasm	0.000178	0.000481	CcSEcCtD
Eprosartan—Dermatitis—Etoposide—peripheral nervous system neoplasm	0.000178	0.00048	CcSEcCtD
Eprosartan—Headache—Etoposide—peripheral nervous system neoplasm	0.000177	0.000478	CcSEcCtD
Eprosartan—Flatulence—Doxorubicin—peripheral nervous system neoplasm	0.000177	0.000477	CcSEcCtD
Eprosartan—Tension—Doxorubicin—peripheral nervous system neoplasm	0.000176	0.000475	CcSEcCtD
Eprosartan—Malaise—Epirubicin—peripheral nervous system neoplasm	0.000175	0.000472	CcSEcCtD
Eprosartan—Nervousness—Doxorubicin—peripheral nervous system neoplasm	0.000175	0.000471	CcSEcCtD
Eprosartan—Vertigo—Epirubicin—peripheral nervous system neoplasm	0.000175	0.00047	CcSEcCtD
Eprosartan—Syncope—Epirubicin—peripheral nervous system neoplasm	0.000174	0.00047	CcSEcCtD
Eprosartan—Back pain—Doxorubicin—peripheral nervous system neoplasm	0.000174	0.000469	CcSEcCtD
Eprosartan—Muscle spasms—Doxorubicin—peripheral nervous system neoplasm	0.000173	0.000466	CcSEcCtD
Eprosartan—Palpitations—Epirubicin—peripheral nervous system neoplasm	0.000172	0.000463	CcSEcCtD
Eprosartan—Loss of consciousness—Epirubicin—peripheral nervous system neoplasm	0.000171	0.00046	CcSEcCtD
Eprosartan—Cough—Epirubicin—peripheral nervous system neoplasm	0.00017	0.000457	CcSEcCtD
Eprosartan—Nausea—Etoposide—peripheral nervous system neoplasm	0.000168	0.000453	CcSEcCtD
Eprosartan—Ill-defined disorder—Doxorubicin—peripheral nervous system neoplasm	0.000167	0.00045	CcSEcCtD
Eprosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—PTPN11—peripheral nervous system neoplasm	0.000166	0.0234	CbGpPWpGaD
Eprosartan—Chest pain—Epirubicin—peripheral nervous system neoplasm	0.000165	0.000446	CcSEcCtD
Eprosartan—Arthralgia—Epirubicin—peripheral nervous system neoplasm	0.000165	0.000446	CcSEcCtD
Eprosartan—Myalgia—Epirubicin—peripheral nervous system neoplasm	0.000165	0.000446	CcSEcCtD
Eprosartan—Anxiety—Epirubicin—peripheral nervous system neoplasm	0.000165	0.000444	CcSEcCtD
Eprosartan—Discomfort—Epirubicin—peripheral nervous system neoplasm	0.000163	0.00044	CcSEcCtD
Eprosartan—AGTR1—Allograft Rejection—ABCB1—peripheral nervous system neoplasm	0.000163	0.0229	CbGpPWpGaD
Eprosartan—Malaise—Doxorubicin—peripheral nervous system neoplasm	0.000162	0.000437	CcSEcCtD
Eprosartan—Dry mouth—Epirubicin—peripheral nervous system neoplasm	0.000162	0.000436	CcSEcCtD
Eprosartan—Vertigo—Doxorubicin—peripheral nervous system neoplasm	0.000162	0.000435	CcSEcCtD
Eprosartan—Syncope—Doxorubicin—peripheral nervous system neoplasm	0.000161	0.000434	CcSEcCtD
Eprosartan—Palpitations—Doxorubicin—peripheral nervous system neoplasm	0.000159	0.000428	CcSEcCtD
Eprosartan—Loss of consciousness—Doxorubicin—peripheral nervous system neoplasm	0.000158	0.000426	CcSEcCtD
Eprosartan—Cough—Doxorubicin—peripheral nervous system neoplasm	0.000157	0.000423	CcSEcCtD
Eprosartan—Shock—Epirubicin—peripheral nervous system neoplasm	0.000156	0.00042	CcSEcCtD
Eprosartan—Thrombocytopenia—Epirubicin—peripheral nervous system neoplasm	0.000155	0.000418	CcSEcCtD
Eprosartan—Tachycardia—Epirubicin—peripheral nervous system neoplasm	0.000155	0.000417	CcSEcCtD
Eprosartan—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	0.000153	0.000413	CcSEcCtD
Eprosartan—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	0.000153	0.000412	CcSEcCtD
Eprosartan—Myalgia—Doxorubicin—peripheral nervous system neoplasm	0.000153	0.000412	CcSEcCtD
Eprosartan—Chest pain—Doxorubicin—peripheral nervous system neoplasm	0.000153	0.000412	CcSEcCtD
Eprosartan—Anxiety—Doxorubicin—peripheral nervous system neoplasm	0.000153	0.000411	CcSEcCtD
Eprosartan—Discomfort—Doxorubicin—peripheral nervous system neoplasm	0.000151	0.000408	CcSEcCtD
Eprosartan—Anorexia—Epirubicin—peripheral nervous system neoplasm	0.000151	0.000407	CcSEcCtD
Eprosartan—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	0.00015	0.000403	CcSEcCtD
Eprosartan—Hypotension—Epirubicin—peripheral nervous system neoplasm	0.000148	0.000399	CcSEcCtD
Eprosartan—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	0.000145	0.000389	CcSEcCtD
Eprosartan—Shock—Doxorubicin—peripheral nervous system neoplasm	0.000144	0.000389	CcSEcCtD
Eprosartan—Thrombocytopenia—Doxorubicin—peripheral nervous system neoplasm	0.000144	0.000387	CcSEcCtD
Eprosartan—Insomnia—Epirubicin—peripheral nervous system neoplasm	0.000143	0.000386	CcSEcCtD
Eprosartan—Tachycardia—Doxorubicin—peripheral nervous system neoplasm	0.000143	0.000386	CcSEcCtD
Eprosartan—Paraesthesia—Epirubicin—peripheral nervous system neoplasm	0.000142	0.000384	CcSEcCtD
Eprosartan—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	0.000142	0.000382	CcSEcCtD
Eprosartan—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	0.000141	0.000381	CcSEcCtD
Eprosartan—Somnolence—Epirubicin—peripheral nervous system neoplasm	0.000141	0.00038	CcSEcCtD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—NTS—peripheral nervous system neoplasm	0.00014	0.0197	CbGpPWpGaD
Eprosartan—Anorexia—Doxorubicin—peripheral nervous system neoplasm	0.00014	0.000377	CcSEcCtD
Eprosartan—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	0.00014	0.000376	CcSEcCtD
Eprosartan—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	0.000138	0.000371	CcSEcCtD
Eprosartan—Hypotension—Doxorubicin—peripheral nervous system neoplasm	0.000137	0.000369	CcSEcCtD
Eprosartan—Fatigue—Epirubicin—peripheral nervous system neoplasm	0.000137	0.000368	CcSEcCtD
Eprosartan—Pain—Epirubicin—peripheral nervous system neoplasm	0.000136	0.000365	CcSEcCtD
Eprosartan—Constipation—Epirubicin—peripheral nervous system neoplasm	0.000136	0.000365	CcSEcCtD
Eprosartan—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	0.000134	0.00036	CcSEcCtD
Eprosartan—Insomnia—Doxorubicin—peripheral nervous system neoplasm	0.000133	0.000358	CcSEcCtD
Eprosartan—Paraesthesia—Doxorubicin—peripheral nervous system neoplasm	0.000132	0.000355	CcSEcCtD
Eprosartan—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	0.000131	0.000353	CcSEcCtD
Eprosartan—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	0.000131	0.000352	CcSEcCtD
Eprosartan—Somnolence—Doxorubicin—peripheral nervous system neoplasm	0.00013	0.000352	CcSEcCtD
Eprosartan—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	0.00013	0.000349	CcSEcCtD
Eprosartan—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	0.000129	0.000348	CcSEcCtD
Eprosartan—Losartan—ABCB1—peripheral nervous system neoplasm	0.000128	1	CrCbGaD
Eprosartan—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	0.000128	0.000344	CcSEcCtD
Eprosartan—Fatigue—Doxorubicin—peripheral nervous system neoplasm	0.000127	0.000341	CcSEcCtD
Eprosartan—Urticaria—Epirubicin—peripheral nervous system neoplasm	0.000126	0.000339	CcSEcCtD
Eprosartan—Pain—Doxorubicin—peripheral nervous system neoplasm	0.000126	0.000338	CcSEcCtD
Eprosartan—Constipation—Doxorubicin—peripheral nervous system neoplasm	0.000126	0.000338	CcSEcCtD
Eprosartan—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	0.000125	0.000338	CcSEcCtD
Eprosartan—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	0.000125	0.000338	CcSEcCtD
Eprosartan—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	0.000121	0.000326	CcSEcCtD
Eprosartan—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	0.00012	0.000323	CcSEcCtD
Eprosartan—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	0.000117	0.000315	CcSEcCtD
Eprosartan—Urticaria—Doxorubicin—peripheral nervous system neoplasm	0.000117	0.000314	CcSEcCtD
Eprosartan—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	0.000116	0.000313	CcSEcCtD
Eprosartan—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	0.000116	0.000313	CcSEcCtD
Eprosartan—Asthenia—Epirubicin—peripheral nervous system neoplasm	0.000114	0.000307	CcSEcCtD
Eprosartan—Pruritus—Epirubicin—peripheral nervous system neoplasm	0.000112	0.000302	CcSEcCtD
Eprosartan—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	0.000109	0.000292	CcSEcCtD
Eprosartan—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	0.000108	0.000291	CcSEcCtD
Eprosartan—AGTR1—GPCR ligand binding—NTS—peripheral nervous system neoplasm	0.000107	0.015	CbGpPWpGaD
Eprosartan—Asthenia—Doxorubicin—peripheral nervous system neoplasm	0.000105	0.000284	CcSEcCtD
Eprosartan—Dizziness—Epirubicin—peripheral nervous system neoplasm	0.000105	0.000283	CcSEcCtD
Eprosartan—Pruritus—Doxorubicin—peripheral nervous system neoplasm	0.000104	0.00028	CcSEcCtD
Eprosartan—AGTR1—GPCR ligand binding—CD55—peripheral nervous system neoplasm	0.000102	0.0144	CbGpPWpGaD
Eprosartan—Vomiting—Epirubicin—peripheral nervous system neoplasm	0.000101	0.000272	CcSEcCtD
Eprosartan—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	0.0001	0.000271	CcSEcCtD
Eprosartan—Rash—Epirubicin—peripheral nervous system neoplasm	0.0001	0.000269	CcSEcCtD
Eprosartan—Dermatitis—Epirubicin—peripheral nervous system neoplasm	9.99e-05	0.000269	CcSEcCtD
Eprosartan—Headache—Epirubicin—peripheral nervous system neoplasm	9.94e-05	0.000268	CcSEcCtD
Eprosartan—Dizziness—Doxorubicin—peripheral nervous system neoplasm	9.71e-05	0.000261	CcSEcCtD
Eprosartan—AGTR1—G alpha (q) signalling events—KNG1—peripheral nervous system neoplasm	9.51e-05	0.0134	CbGpPWpGaD
Eprosartan—Nausea—Epirubicin—peripheral nervous system neoplasm	9.42e-05	0.000254	CcSEcCtD
Eprosartan—AGTR1—Peptide ligand-binding receptors—KNG1—peripheral nervous system neoplasm	9.39e-05	0.0132	CbGpPWpGaD
Eprosartan—Vomiting—Doxorubicin—peripheral nervous system neoplasm	9.33e-05	0.000251	CcSEcCtD
Eprosartan—Rash—Doxorubicin—peripheral nervous system neoplasm	9.25e-05	0.000249	CcSEcCtD
Eprosartan—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	9.25e-05	0.000249	CcSEcCtD
Eprosartan—Headache—Doxorubicin—peripheral nervous system neoplasm	9.19e-05	0.000248	CcSEcCtD
Eprosartan—CYP2C9—Constitutive Androstane Receptor Pathway—ABCB1—peripheral nervous system neoplasm	9.19e-05	0.0129	CbGpPWpGaD
Eprosartan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—peripheral nervous system neoplasm	8.75e-05	0.0123	CbGpPWpGaD
Eprosartan—Nausea—Doxorubicin—peripheral nervous system neoplasm	8.72e-05	0.000235	CcSEcCtD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—KNG1—peripheral nervous system neoplasm	8.51e-05	0.012	CbGpPWpGaD
Eprosartan—AGTR1—Allograft Rejection—CASP3—peripheral nervous system neoplasm	8.26e-05	0.0116	CbGpPWpGaD
Eprosartan—ABCC2—NRF2 pathway—SLC2A1—peripheral nervous system neoplasm	7.86e-05	0.0111	CbGpPWpGaD
Eprosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—AKT1—peripheral nervous system neoplasm	6.45e-05	0.00907	CbGpPWpGaD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	6.3e-05	0.00886	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	6.03e-05	0.00849	CbGpPWpGaD
Eprosartan—ABCC2—NRF2 pathway—HGF—peripheral nervous system neoplasm	6.03e-05	0.00848	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—NTS—peripheral nervous system neoplasm	5.48e-05	0.00771	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—CD55—peripheral nervous system neoplasm	5.25e-05	0.00739	CbGpPWpGaD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—PTPN11—peripheral nervous system neoplasm	5.17e-05	0.00727	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	4.8e-05	0.00675	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	4.76e-05	0.0067	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	4.57e-05	0.00643	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	4.19e-05	0.0059	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—VIP—peripheral nervous system neoplasm	4.15e-05	0.00584	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	3.83e-05	0.00539	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	3.3e-05	0.00464	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—NTS—peripheral nervous system neoplasm	3.24e-05	0.00455	CbGpPWpGaD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—peripheral nervous system neoplasm	3.11e-05	0.00437	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CD55—peripheral nervous system neoplasm	3.1e-05	0.00437	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	2.71e-05	0.00381	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	2.52e-05	0.00354	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	2.46e-05	0.00346	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—VIP—peripheral nervous system neoplasm	2.45e-05	0.00345	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	2.37e-05	0.00334	CbGpPWpGaD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—peripheral nervous system neoplasm	2.27e-05	0.0032	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	2.26e-05	0.00318	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PPIP5K2—peripheral nervous system neoplasm	2.17e-05	0.00306	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	2.15e-05	0.00303	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	2.03e-05	0.00285	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	1.99e-05	0.0028	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	1.7e-05	0.00239	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	1.5e-05	0.0021	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—HSD17B12—peripheral nervous system neoplasm	1.47e-05	0.00207	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—KNG1—peripheral nervous system neoplasm	1.45e-05	0.00205	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	1.39e-05	0.00195	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—GNAS—peripheral nervous system neoplasm	1.27e-05	0.00179	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	1.22e-05	0.00172	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GNS—peripheral nervous system neoplasm	1.06e-05	0.00149	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—NME1—peripheral nervous system neoplasm	1.02e-05	0.00143	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—COX2—peripheral nervous system neoplasm	9.79e-06	0.00138	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	8.99e-06	0.00127	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	8.84e-06	0.00124	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	6.98e-06	0.000983	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	6.58e-06	0.000926	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ENO2—peripheral nervous system neoplasm	6.43e-06	0.000905	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	6.4e-06	0.0009	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	6.34e-06	0.000892	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	5.81e-06	0.000817	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—BCHE—peripheral nervous system neoplasm	5.43e-06	0.000764	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	5.31e-06	0.000748	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—SLC2A1—peripheral nervous system neoplasm	5.18e-06	0.000729	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—TH—peripheral nervous system neoplasm	5.11e-06	0.000719	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—MYC—peripheral nervous system neoplasm	4.95e-06	0.000696	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GNAS—peripheral nervous system neoplasm	4.17e-06	0.000587	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ABCB1—peripheral nervous system neoplasm	4.09e-06	0.000576	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—TP53—peripheral nervous system neoplasm	4.06e-06	0.000572	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	3.89e-06	0.000547	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	3.43e-06	0.000483	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—AKT1—peripheral nervous system neoplasm	1.13e-06	0.000158	CbGpPWpGaD
